The coalition recently urged stakeholders to support the Facilitating Innovative Nuclear Diagnostics Act of 2021, which would update “arcane” payment policies.
Oncology experts with the University of Washington in Seattle’s Cancer Research Center shared their findings in the Journal of Nuclear Medicine's February issue.
As part of the contract, Los Angeles-based ImaginAb will provide Pfizer will its 89Zr CD8 immuno-PET agent, which is used to image CD8 T cells in cancer patients.
“This offers the potential to provide diagnostic imaging using copper-64 to plan individualized treatments with copper-67 agents for a wide range of cancer patients," Australian researchers explained in the Journal of Nuclear Medicine.